Monte Rosa Therapeutics Analyst Ratings
Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Maintains $16 Price Target
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)
Buy Rating Affirmed for Monte Rosa Therapeutics Amidst Promising Drug Pipeline and Stable Financials
Monte Rosa Therapeutics (GLUE) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
Wells Fargo Gives a Buy Rating to Monte Rosa Therapeutics (GLUE)
Promising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa Therapeutics
Monte Rosa Therapeutics (GLUE) Receives a Buy From Piper Sandler
Monte Rosa Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)
Analysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $11
Monte Rosa Therapeutics Analyst Ratings
Hold Rating on Monte Rosa Therapeutics Due to Clinical Uncertainties and Delayed Launch of MRT-2359: An Analysis
Monte Rosa Therapeutics Analyst Ratings
Berenberg Bank Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics (GLUE) Gets a Hold From SVB Securities